Abstract:Background: Primary biliary cholangitis (PBC) is characterized by nonsuppurative destructive cholangitis and is thought to be an autoimmune disorder. Currently, ursodeoxycholic acid (UDCA) is the only FDA approved first line therapy for PBC, but up to nearly one-third of patients do not achieve a complete response to this treatment. Adaptive immune cells, including T cells and B cells, have been found in the portal tracts and the bile duct epithelium and play a role in the pathogenesis of PBC, but the importance of these cells for evaluating the therapeutic response to UDCA in PBC has not yet been studied. Methods: In this study, we collected liver puncture biopsy specimens from 34 matched patients with PBC before and after UDCA treatment and investigated the relationship between the infiltration of adaptive immune cells and the treatment response to UDCA. The extent of immune cell infiltration was determined by immunohistochemical analysis. Responses were defined based on Paris-I criteria Results: After 1 year of treatment, 25/34 patients responded to UDCA treatment according to Paris-I criteria (responders), and 9/34 patients were nonresponders. Immunohistochemical analysis showed that UDCA responders exhibited significantly less CD4+ T cell infiltration after UDCA treatment than before (50.4 7.5/HPF vs 30.0 +/- 7.9/HPF, P = 0.002). In contrast, UDCA nonresponders exhibited significantly more CD4+ T cell infiltration after UDCA treatment than before (32.2 +/- 8.0/HPF vs 75.0 +/- 13.9/HPF, P = 0.045). Moreover, patients who exhibited a reduction in CD4+ T cell infiltration after UDCA treatment had a higher response rate than those that exhibited an increase in CD4+ T cell infiltration (85.7 % vs 53.8 %, P = 0.041). However, CD3+ T cell, CD8+ T cell, and CD20+ B cell infiltration was not significantly different before and after treatment in either UDCA responders or nonresponders. Furthermore, we found that the number of infiltrating T-bet+ Th1 cells was much lower after UDCA treatment than before in responders (10.5 +/- 5.7/HPF vs. 5.16 +/- 4.0/HPF, P = 0.0214) but much higher in nonresponders after treatment than before (1.89 +/- 1.2/HPF vs. 12.3 +/- 5.4/HPF, P = 0.043). However, there was no difference in the extent of GATA3+ Th2 or FOXP3+ Treg infiltration before and after treatment in either UDCA responders or nonresponders. Conclusion: Collectively, our results suggest that a decrease in the number of liver-infiltrating CD4+ Th1 cells is associated with a good response of PBC patients to UDCA treatment. Immunohistochemical analysis of CD4 and T-bet in PBC liver specimens may be a potential approach for evaluating the therapeutic response to UDCA.

Changes in plasma bile acid profiles after partial internal biliary diversion in PFIC2 patients.

Evidence for the Association Between IgG‐antimitochondrial Antibody and Biochemical Response to Ursodeoxycholic Acid Treatment in Primary Biliary Cholangitis

Comprehensive bile acid profiling in hereditary intrahepatic cholestasis: Genetic and clinical correlations.

Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials.

A Report of 2 Infant Siblings with Progressive Intrahepatic Familial Cholestasis Type 1 and a Novel Homozygous Mutation in the ATP8B1 Gene Treated with Partial External Biliary Diversion and Liver Transplant

Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis

Simultaneous total internal biliary diversion during liver transplantation for progressive familial intrahepatic cholestasis Type 1: Standard of care?

Changes in Microbiota and Metabolites Are Associated With Effects of Bile Acid Sequestrant on Icteric Primary Biliary Cholangitis

Gut Microbial Profile is Altered in Primary Biliary Cholangitis and Partially Restored after UDCA Therapy

Short-term Outcomes and Prognostic Factors of Cholecystojejunocolonic Anastomosis for PFIC and Alagille Syndrome

Alterations in microbiota and their metabolites are associated with beneficial effects of bile acid sequestrant on icteric primary biliary Cholangitis

Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis

Clinical and Genetic Characterization of Pediatric Patients with Progressive Familial Intrahepatic Cholestasis Type 3 (PFIC3): Identification of 14 Novel ABCB4 Variants and Review of the Literatures

Dysregulation of Circulating FGF19 and Bile Acids in Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome

Serum metabolic profiling of targeted bile acids reveals potentially novel biomarkers for primary biliary cholangitis and autoimmune hepatitis

Decreased Infiltration of CD4+ Th1 Cells Indicates a Good Response to Ursodeoxycholic Acid (UDCA) in Primary Biliary Cholangitis.

Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis

Immunosuppression induces regression of fibrosis in primary biliary cholangitis with moderate-to-severe interface hepatitis

Maralixibat for the treatment of PFIC: Long‐term, IBAT inhibition in an open‐label, Phase 2 study

IDDF2022-ABS-0112 Clinical Features in Primary Biliary Cholangitis: a Retrospective Analysis of 52 Cases

Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials